<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00850863</url>
  </required_header>
  <id_info>
    <org_study_id>23437</org_study_id>
    <nct_id>NCT00850863</nct_id>
  </id_info>
  <brief_title>Systemic Inflammation in Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>Acute and Chronic Inflammatory Responses Induced by Smoking in Individuals Being Susceptible and Non-Susceptible for Development of COPD: From Specific Disease Phenotyping Towards Novel Therapy (Study 2).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Top Institute Pharma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Academisch Ziekenhuis Maastricht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nycomed</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Top Institute Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      COPD is ranked number 3 by the WHO list of important diseases worldwide and is the only&#xD;
      disease with increasing mortality. The pathogenesis of cigarette smoke-induced COPD is&#xD;
      obscure, therefore more insight is needed to design effective anti-inflammatory agents.&#xD;
      Recently it has become clear that cigarette smoke-induced inflammation is not only present in&#xD;
      the lungs but also in the blood, and that this systemic inflammation has important&#xD;
      consequences for the clinical expression of COPD. The investigators hypothesize that healthy&#xD;
      individuals who are susceptible to cigarette smoking demonstrate a higher and aberrant&#xD;
      systemic inflammatory response to cigarette smoke. This susceptibility is caused by&#xD;
      heterogeneous factors and is associated with various polymorphic genes that interact with&#xD;
      each other and with the environment.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
        -  To study systemic inflammation in individuals who are or are not susceptible to develop&#xD;
           COPD.&#xD;
&#xD;
        -  To characterize the switch to chronicity of the systemic inflmmatory response in COPD&#xD;
&#xD;
        -  To determine whether the type and severity of the systemic inflammation contributes to&#xD;
           the clinical outcome of COPD&#xD;
&#xD;
        -  To compare between subjects who are or are not susceptible to develop COPD in peripheral&#xD;
           blood, the corticosteroid responsiveness in vitro, and to unravel underlying mechanisms.&#xD;
&#xD;
        -  To study the role of candidate genes that may play a role in the development of fixed&#xD;
           airway obstruction, and to identify clues for patient's responsiveness to specific drugs&#xD;
&#xD;
        -  To develop new biological and clinical markers for the early diagnosis and monitoring of&#xD;
           COPD&#xD;
&#xD;
        -  To define possible mediators involved in the early induction of COPD in susceptible&#xD;
           smokers, and to define new drug targets&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2009</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Systemic inflammation assessed by measurement of expression of established and newly developed markers on innate immune cells; genomic and proteomic analysis of innate immune cells and measurement of pro- and anti-inflammatory cytokines in plasma/serum</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Extensive clinical characterisation of: a) young healthy individuals with low number of pack years who have a high and low familial risk to develop COPD; b) older individuals with higher number of pack years with either a normal lung function or COPD.</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Important clinical endpoints include symptoms, lung function, Bode-index, CT-scanning of the lung.</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of candidate genes (SNPs) for COPD between the different groups and relations with systemic inflammation.</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_groups>9</number_of_groups>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <description>20 healthy individuals not susceptible for COPD (age 18-40 years, 0 &lt; pack years &gt; 10, FEV1/FVC &gt;70% , FEV1 &gt;85% predicted)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <description>30 healthy individuals susceptible for COPD (age 40-75years, pack years &gt;20, FEV1/FVC &gt; 70%, FEV1 &gt; 85% predicted)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <description>20 healthy individuals very susceptible for COPD (age 18-40 year, 0 &lt; pack years &gt; 10, FEV1/FVC &gt; 70%, FEV1 &gt; 85% predicted)and high prevalance of COPD in smoking family members older than 45 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D1</arm_group_label>
    <description>30 COPD patients with GOLD stage I (age 40-75 years, Pack years &gt; 10, FEV1/FVC ≤ 70%, FEV1 &gt; 80% predicted)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D2</arm_group_label>
    <description>30 COPD patients with GOLD stage II (age 40-75 years, Pack years &gt; 10, FEV1/FVC ≤ 70%, FEV1 50-80 predicted)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D3</arm_group_label>
    <description>30 COPD patients with GOLD stage III (age 40-75 years, Pack years &gt; 10, FEV1/FVC ≤ 70%, FEV1 30-50% predicted)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D4</arm_group_label>
    <description>30 COPD patients with GOLD stage IV (age 40-75 years,Pack years &gt; 10, FEV1/FVC ≤ 70%, FEV1 30% predicted)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E</arm_group_label>
    <description>20 healthy individuels very susceptible for COPD ( Age 18-40 years,0 &lt; Pack years &gt; 10, FEV1/FVC &gt;70%, FEV1 &gt; 85% predicted, and one of the smoking family members has severe early onset COPD or mild COPD with very low smoke exposure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F</arm_group_label>
    <description>30 COPD patients who are highly susceptible (age &gt; 53 years with Pack years &gt; 10 , FEV1/FVC ≤ 70% and FEV1 &lt; 40% predicted) or (age &gt;18 years with 0 &lt; pack years &gt; 5, FEV1/FVC ≤ 70% and FEV1 &lt; 80% predicted)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy individuels and COPD patients. For detail description see Groups/Cohorts.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Age ≥18 and ≤75 years&#xD;
&#xD;
          -  Age, pack years, FEV1/FVC and FEV1% predicted must fit in one of the 9 groups of the&#xD;
             study population&#xD;
&#xD;
          -  Physically and mentally able to undergo the total study protocol&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in another study&#xD;
&#xD;
          -  Alpha-1-antitrypsin deficiency&#xD;
&#xD;
          -  Selected grade 1-3 co-morbidity listed in the ACE-27&#xD;
&#xD;
          -  Active pulmonary infection like tuberculosis, pneumonia, flue, tracheobronchitis&#xD;
&#xD;
          -  Active extra-pulmonary infection like hepatitis A-C, cystitis, gastro-enteritis etc&#xD;
&#xD;
          -  Pulmonary diseases like sarcoidosis, pulmonary fibrosis, silicosis, hypersensitivity&#xD;
             pneumonitis, asthma&#xD;
&#xD;
          -  Life threatening diseases like carcinoma, AIDS (including HIV+), acute leukaemia etc&#xD;
&#xD;
          -  Medication that may affect the results of the study: NSAID's, immunosuppressive agents&#xD;
             like prednisolon, metotrexate, azathioprine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan-Willem Lammers, Dr. Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leo Koenderman, Dr. Prof.</last_name>
    <phone>+31 88 7557255</phone>
    <email>l.koenderman@umcutrecht.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3508GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leo Koenderman, Dr. Prof</last_name>
      <phone>+31 88 7557255</phone>
      <email>l.koenderman@umcutrecht.nl</email>
    </contact>
    <investigator>
      <last_name>Jan-Willem Lammers, Dr. Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leo Koenderman, Dr. Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <study_first_submitted>February 24, 2009</study_first_submitted>
  <study_first_submitted_qc>February 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2009</study_first_posted>
  <last_update_submitted>February 24, 2009</last_update_submitted>
  <last_update_submitted_qc>February 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Professor Dr. J-W.J Lammers</name_title>
    <organization>University Medical Center Utrecht</organization>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Smoking</keyword>
  <keyword>Susceptibility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

